Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.16%||162.91||0.7%||$988.77m|
|MRK||Merck & Co., Inc.||-0.11%||73.28||0.7%||$937.00m|
|LLY||Eli Lilly & Co.||-2.07%||221.72||1.1%||$592.16m|
|BMY||Bristol-Myers Squibb Co.||0.02%||59.85||1.0%||$591.86m|
|CRVS||Corvus Pharmaceuticals, Inc.||-10.17%||6.89||0.7%||$147.73m|
|RPRX||Royalty Pharma Plc||-1.43%||36.62||0.1%||$118.91m|
|APLS||Apellis Pharmaceuticals, Inc.||0.20%||35.13||0.0%||$104.57m|
Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.